- NCIt
- C7480
Loading cancer entity…
Loading cancer entity…
Clinical trials
744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00066456 | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 13 | Gynecologic Oncology GroupNETWORK | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00002960 | SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) | completed | Phase 1 | 59 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT01940172 | Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer | completed | Phase 1 | 27 | TetraLogic PharmaceuticalsINDUSTRY | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00702299 | Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | completed | Phase 1 | 15 | University of ArizonaOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | AmgenINDUSTRY | 3 | Oct 14, 2015 | clinicaltrials |
| NCT00770536 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | completed | Phase 1 | 103 | AmgenINDUSTRY | 3 | Sep 29, 2015 | clinicaltrials |
| NCT01652794 | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00060359 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 32 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2015 | clinicaltrials |
| NCT00006981 | Immunotoxin Therapy in Treating Patients With Advanced Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00066651 | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00959582 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 22, 2015 | clinicaltrials |
| NCT00352300 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | completed | Phase 1 | 43 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00814086 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT01294293 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 1 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT00550784 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 8 | City of Hope Medical CenterOTHER | 0 | Oct 7, 2014 | clinicaltrials |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
| NCT00006235 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | — | Gynecologic Oncology GroupNETWORK | 0 | Jul 9, 2013 | clinicaltrials |
| NCT00004082 | Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors | completed | Phase 1 | — | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00055614 | Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00006041 | Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00021034 | Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00003380 | Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | terminated | Phase 1 | — | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00003382 | Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer | terminated | Phase 1 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00058435 | Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00017017 | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00003385 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 48 | Gynecologic Oncology GroupNETWORK | 2 | May 27, 2013 | clinicaltrials |
| NCT00003967 | Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Gynecologic Oncology GroupNETWORK | 1 | May 27, 2013 | clinicaltrials |
| NCT00842452 | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 26 | Steven Waggoner, MDOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00003358 | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | completed | Phase 1 | 11 | AA SecordOTHER | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00028912 | Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00006391 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | NYU Langone HealthOTHER | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00753480 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | suspended | Phase 1 | 56 | Genentech, Inc.INDUSTRY | 1 | Nov 7, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Feb 11, 2016source: clinicaltrials